5:49 PM
 | 
Dec 26, 2012
 |  BC Extra  |  Politics & Policy

FDA to discuss minimal residual disease as surrogate endpoint

The American Society of Clinical Oncology and FDA's Office of Hematology and Oncology Products will jointly hold public workshops to discuss the regulatory, scientific, and clinical basis for using minimal residual disease (MRD)...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >